Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. METHODS: We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. RESULTS: In nested case-control analyses from two prospective cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7). In two retrospective case-control cohorts for the evaluation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary heart disease. CHIP carriers with these mutations also had increased coronary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from homozygous or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow. Analyses of macrophages from Tet2 knockout mice showed elevated expression of several chemokine and cytokine genes that contribute to atherosclerosis. CONCLUSIONS: The presence of CHIP in peripheral-blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That subjects with clonal hematopoiesis are more susceptible to develop nonhematological, most notably cardiovascular, disease”
From Aging of hematopoietic stem cells (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tet2 and Ppm1d mutant murine models have demonstrated an increased inflammatory signature in mutant macrophages, with heightened inflammatory cytokine production upon pro-inflammatory stimulation in vitro [31,32,69,70].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated IL-8 and IL-1β levels have been reported in patients with TET2 CH in the Pakistan Risk of Myocardial Infarction Study (PROMIS) [20,32]”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measured
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Self-citationMacrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Cited by
Items 701–800 of 1,015
Gutierrez‐Rodrigues, F., Wells, K. V., Jones, A. I., Hironaka, D., Rankin, C., Gadina, M., Sikora, K. A., Alemu, L., Calado, R. T., Quinn, K. A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224933 · Cited by 37
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes
Nead, K. T., Kim, T., Joo, L., McDowell, T. L., Wong, J., Chan, I. C. C., Brock, E., Zhao, J., Xu, T., Tang, C. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012929 · Cited by 38
Steensma, D. P. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00547-3 · Cited by 37
Gaibazzi, N., Picano, E., Suma, S., Garibaldi, S., Porter, T. R., Botti, A., Tuttolomondo, D., Tedeschi, A., & Lorenzoni, V. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.01.007 · Cited by 35
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications
Cuomo, A., Pirozzi, F., Attanasio, U., Franco, R., Elia, F., Rosa, E. D., Russo, M., Ghigo, A., Ameri, P., Tocchetti, C. G., et al. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00990-z · Cited by 39
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future
Murphy, A. J., & Febbraio, M. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00580-5 · Cited by 36
Williams, L. S., Williams, K. M., Gillis, N., Bolton, K. L., Damm, F., Deuitch, N. T., Farhadfar, N., Gergis, U. S., Keel, S., Michelis, F. V., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.018 · Cited by 45
Social Determinants of Health in Cardio-Oncology
Baah, F. O., Sharda, S., Davidow, K. A., Jackson, S., Kernizan, D., Jacobs, J. A., Baumer, Y., Schultz, C. L., Baker-Smith, C. M., & Powell‐Wiley, T. M. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.02.009 · Cited by 41
Cardiovascular Aging and Exercise: Implications for Heart Failure Prevention and Management
Subramanian, V., Tucker, W. J., Peters, A. E., Upadhya, B., Kitzman, D. W., & Pandey, A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325531 · Cited by 42
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease
von Scheidt, M., Adkar, S. S., Krefting, J., Hoermann, G., Meggendorfer, M., Bauer, S., Mitchell, S. R., Pugach, I., Frieß, C., Ma, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf602 · Cited by 49
Self-citationSteensma, D. P. (2018) · Blood · doi:10.1182/blood-2018-06-860882 · Cited by 34
Belderbos, M. E., Jacobs, S., Koster, T., Ausema, A., Weersing, E., Zwart, E., de Haan, G., & Bystrykh, L. V. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.026 · Cited by 49
“Finally, as (age-related) reduction in the number of HSC clones is associated with various adverse health effects, administration of sufficient HSCs may be favorable in the long term as well [9-11].”
BackgroundBone Marrow Senescence and the Microenvironment of Hematological Malignancies
Hellmich, C., Moore, J. A., Bowles, K. M., & Rushworth, S. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00230 · Cited by 35
“These mutations are commonly associated with myeloproliferative disorders, MDS and AML but clonal hematopoiesis associated with these mutations has also been linked to other age-related pathologies including cardiovascular disease even in the absence of any hematological disorder (41).”
BackgroundNeuroimmune interactions in cardiovascular diseases
Carnevale, D., & Lembo, G. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa151 · Cited by 35
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis
Miller, P. G., Sperling, A. S., Gibson, C. J., Viswanathan, K., Castellano, C. A., McConkey, M. E., Ceremsak, J. J., Taylor, M. S., Birndt, S., Perner, F., et al. (2020) · Blood · doi:10.1182/blood.2020008206 · Cited by 35
Self-citationItaliani, P., Camera, G. D., & Boraschi, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.566309 · Cited by 39
“For example, it could affect TET2, one of the genes involved in clonal hematopoiesis, whose mutations are associated with increased risk of hematologic cancer and cardiovascular diseases (101, 102).”
BackgroundEpidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis, R. M., Zeidan, A. M., Wang, R., & Podoltsev, N. A. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.11.005 · Cited by 36
Zhang, X., Sun, J., Canfrán‐Duque, A., Aryal, B. K., Tellides, G., Chang, Y. J., Suárez, Y., Osborne, T. F., & Fernandez-Hernando, C. F. (2021) · JCI Insight · doi:10.1172/jci.insight.147984 · Cited by 37
“Deficiency of DNA-demethylating enzyme TET methylcytosine dioxygenase 2 (TET2) in hematopoietic cells accelerates atherosclerosis by elevating expression of cytokines and chemokines and NLRP3 inflammasome activation (4, 5).”
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?
Kusne, Y. N., Fernandez, J. A., & Patnaik, M. M. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.10.004 · Cited by 35
Cardiovascular Disease Risk Modeling for Astronauts: Making the Leap From Earth to Space
Huff, J. L., Plante, I., Blattnig, S. R., Norman, R. B., Little, M. P., Khera, A., Simonsen, L. C., & Patel, Z. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.873597 · Cited by 39
“While the level of risk is dependent on the number of mutant clones, the specific mutations involved, and existence of other risk factors, the presence of CHIP is estimated to almost double the CVD risk and thus has potential to be an important variable as astronauts age (103, 104).”
BackgroundGenomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease
Natarajan, P. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318181 · Cited by 37
Self-citationMcCune, J. M., & Weissman, I. L. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.10.003 · Cited by 35
“, 2014), and surprisingly have a 2-fold relative risk for atherosclerosis (Jaiswal et al., 2017).”
BackgroundEbert, B. L., & Libby, P. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0737 · Cited by 37
Self-citationEmergency myelopoiesis in solid cancers
Aliazis, K., Yenyuwadee, S., Phikulsod, P., & Boussiotis, V. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19656 · Cited by 36
“156 In addition to de novo development, CH can be induced during haematopoietic cell regeneration secondary to chemotherapy for solid tumours.”
Polizio, A. H., Marino, L., Min, K.-D., Yura, Y., Rolauer, L., Cochran, J. D., Evans, M. A., Park, E., Doviak, H., Miura‐Yura, E., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324492 · Cited by 35
“6 As individuals age, they also increasingly exhibit the condition of CH, which has been causally linked to atherosclerotic cardiovascular disease 28,35 and heart failure.”
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment
Arnold, N., & Köenig, W. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70020 · Cited by 36
“39,40 Of major interest, atherosclerotic plaque growth was highly associated with enhanced IL-1 β /IL-6 production in mutant mice through overactivation of the NLRP3 inflammasome.”
Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases
Wu, H., Wei, J., Yu, Y., Wang, N., & Tan, X. W. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20080 · Cited by 36
“Specifically, aging T cells display a restricted receptor repertoire, limiting their ability to respond to new antigens and increasing the risk of self-reactivity [41].”
Trained immunity and atherosclerotic cardiovascular disease
Riksen, N. P. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000628 · Cited by 34
“Two studies have reported independently that CHIP correlates with an increased risk of atherosclerotic cardiovascular disease [34,35].”
BackgroundStem cell donors should not be screened for clonal hematopoiesis
Gibson, C. J., & Lindsley, R. C. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000395 · Cited by 34
“Retrospective studies in population-level cohorts defined the scope of CH and identified specific links to adverse clinical outcomes, including an increased relative risk of hematologic malignancies,(6,7) increased risk of ischemic cardiovascular disease and stroke, and elevated all-cause mortality.(6,8) Laboratory mo…”
BackgroundSelf-citationThe role of host environment in cancer evolution
Solary, É., & Laplane, L. (2020) · Evolutionary Applications · doi:10.1111/eva.13039 · Cited by 33
“Clonal hematopoiesis is associated also with a substantial increase in the risk of cardiovascular and other diseases of aging (Jaiswal et al., 2017).”
BackgroundWolfien, M., Klatt, D., Salybekov, A. A., Ii, M., Horii, M., Gaebel, R., Philippou‐Massier, J., Schrinner, E., PERFECT Trial and Vascular Regenera Group, Blum, H., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102862 · Cited by 34
“However, disorders of clonal hematopoiesis of indeterminate pathology (CHIP) has been described in hematological and cardiovascular disease patients and associated to congenital or somatic DNA mutations [4,5].”
BackgroundAssociation Between Variation in Red Cell Size and Multiple Aging-Related Outcomes
Kim, K. M., Lui, L., Browner, W. S., Cauley, J. A., Ensrud, K. E., Kado, D. M., ORWOLL, E. S., Schousboe, J. T., & Cummings, S. R. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa217 · Cited by 33
“Clonal hematopoiesis is known to be associated with the risks of diseases that are representative of aging-related chronic diseases, such as diabetes, cardiovascular disease, and ischemic stroke (20,27), but has not been reported with the other aging-related outcomes included in our analysis.”
BackgroundOran, B., Champlin, R. E., Wang, F., Tanaka, T. N., Saliba, R. M., Alatrash, G., Garcia‐Manero, G., Kantarjian, H. M., Cao, K., Shpall, E. J., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01312-3 · Cited by 38
Genetic Determinants of Peripheral Artery Disease
Klarin, D. M., Tsao, P. S., & Damrauer, S. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318327 · Cited by 35
Jovani, M., Liu, E. E., Paniagua, S. M., Lau, E. S., Li, S. X., Takvorian, K. S., Kreger, B. E., Splansky, G. L., de Boer, R. A., Joshi, A. D., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab282 · Cited by 34
“For example, clonal haematopoiesis of indeterminate potential, which increases the risk of haematologic malignancies, seems also associated with atherosclerotic CVD, probably by the mediation of aberrant inflammatory activity.(8) In a recent experimental model a direct link between heart failure (HF) and increased tum…”
BackgroundMacrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes
Pronier, E., Imanci, A., Selimoglu‐Buet, D., Badaoui, B., Itzykson, R., Roger, T., Jego, C., Naimo, A., Francillette, M., Breckler, M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03057-w · Cited by 34
Carballo-Perich, L., Puigoriol‐Illamola, D., Bashir, S., Terceño, M., Silva, Y., Gubern, C., & Serena, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095149 · Cited by 35
“Similarly, two studies have demonstrated the role of TET2 in reducing pro-inflammatory cytokine and chemokine expression as well as inflammasome activation, thus preventing atherosclerosis [54,55].”
BackgroundHematology 2022—what is complete HLA match in 2022?
Spellman, S. R. (2022) · Hematology · doi:10.1182/hematology.2022000326 · Cited by 33
Next-Generation Sequencing to Diagnose Suspected Genetic Disorders
Li, S., & Gerstein, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1814955 · Cited by 33
Todor, S. B., Ichim, C., Boicean, A., & Mihăilă, R. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080496 · Cited by 33
“While individuals with CHIP, in most cases, might not acquire hematological malignancies, they are most likely susceptible to cardiac comorbidities and enhanced arterial plaque buildup [100].”
BackgroundTP53-mutated acute myeloid leukemia: how can we improve outcomes?
Sallman, D. A., & Stahl, M. F. (2024) · Blood · doi:10.1182/blood.2024024245 · Cited by 34
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., Gotlib, J. R., Haferlach, T., Hoermann, G., Hermine, O., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.024 · Cited by 34
“Over the past few years, a number of projects have been initiated to explore whole genome profiles in healthy people or individuals at risk for development of cancer or other diseases (Altman, 2013; Jaiswal et al., 2014; Jaiswal et al., 2017; Khoury et al., 2003; Vassy et al., 2014; Yang et al., 2013).”
InfluentialAlduaij, W., McNamara, C. J., Schuh, A. C., Arruda, A., Sukhai, M. A., Kanwar, N., Thomas, M., Spiegel, J. Y., Kennedy, J. A., Stockley, T. L., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000044 · Cited by 32
Chitre, S., Stölzel, F., Cuthill, K., Streetly, M., Graham, C., Dill, C., Mohamedali, A. M., Smith, A., Schetelig, J., Altmann, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0208-8 · Cited by 32
Ayachi, S., Buscarlet, M., & Busque, L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.008 · Cited by 33
Spinetti, G., Sangalli, E., Tagliabue, E., Maselli, D., Colpani, O., Ferland-McCollough, D., Carnelli, F., Orlando, P., Paccagnella, A., Furlan, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2227 · Cited by 32
Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells
Russkamp, N. F., Myburgh, R., Kiefer, J. D., Neri, D., & Manz, M. G. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.01.003 · Cited by 34
“CHIP has been linked to several hematopoietic and non-hematopoietic disorders [11,15].”
BackgroundNewell, L. F., Williams, T. P., Liu, J., Yu, Y., Chen, Y., Booth, G. C., Knight, R. J., Goslee, K., Cook, R. J., Leonard, J. T., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.04.014 · Cited by 35
Anti-inflammatory Strategies in Atherosclerosis
Bugger, H., & Zirlik, A. (2021) · Hämostaseologie · doi:10.1055/a-1661-0020 · Cited by 34
JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis
Soudet, S., Roy, G. L., Cadet, E., Michaud, A., Morel, P., Marolleau, J. P., & Sevestre, M. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.011 · Cited by 32
Zeidan, A. M., Bewersdorf, J. P., Buckstein, R. J., Sekeres, M. A., Steensma, D. P., Platzbecker, U., Loghavi, S., Boultwood, J., Bejar, R. L., Bennett, J. M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01724-9 · Cited by 34
“With the growing body of evidence demonstrating an association of CHIP and CCUS with cardiovascular, cerebrovascular, and pulmonary diseases as well as other aging-related diseases, the inclusion of CHIP and CCUS as clearly defined disease entities in the WHO 2022 and ICC definition will certainly have implications be…”
BackgroundNinni, S., Dombrowicz, D., Kuznetsova, T., Vicario, R., Gao, V., Molendi‐Coste, O., Haas, J. T., Woitrain, E., Coisne, A., Neele, A. E., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.036 · Cited by 34
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
“The presence of CHIP has been linked to a two-fold increase in the occurrence of CAD [129].”
Erbilgin, A., Seldin, M. M., Wu, X., Mehrabian, M., Zhou, Z., Qi, H., Dabirian, K. S., Packard, R. R. S., Hsieh, W. Y., Bensinger, S. J., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311266 · Cited by 32
Macrophages in Cardiovascular Homeostasis and Disease
Cao, D. J. (2018) · Circulation · doi:10.1161/circulationaha.118.035736 · Cited by 32
Aviv, A., & Levy, D. A. (2018) · Circulation · doi:10.1161/circulationaha.118.038434 · Cited by 32
“This would explain (1) the age-dependent increase in CHIP, because, as they age, more individuals converge toward the telomere brink from which CHIP offers escape; (2) the higher prevalence of CHIP in men versus women; and (3) the disproportionally high frequency of CHIP mutations in comparison with other randomly acq…”
BackgroundThe March of Monocytes in Atherosclerosis: One Cell at a Time
Gupta, R. M., Lee, V. S., & Libby, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316981 · Cited by 36
Self-citationLifelong partners: Gut microbiota-immune cell interactions from infancy to old age
Brown, J. A., Bashir, H., & Zeng, M. Y. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.01.006 · Cited by 35
Recent Advances in Immunothrombosis and Thromboinflammation
Kaiser, R. W. J., Gold, C., & Stark, K. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2523-1821 · Cited by 37
Barbui, T., Stefano, V. D., Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., & Barosi, G. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0225-5 · Cited by 32
Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
Duployez, N., Demonchy, J., Berthon, C., Goutay, J., Caplan, M., Moreau, A.-S., Bignon, A. L., Marceau‐Renaut, A., Garrigue, D., Raczkiewicz, I., et al. (2020) · Cancers · doi:10.3390/cancers12071992 · Cited by 32
“Case control studies have shown that CHIP was associated with a higher risk of hematological cancer [4,5], as expected, but also with an increase in incident coronary heart disease, ischemic stroke and all-cause mortality [4,9,10], and chronic obstructive pulmonary disease [6,7].”
BackgroundThrombosis in hematological malignancies: mechanisms and implications
Horowitz, N. A., & Brenner, B. (2020) · Thrombosis Research · doi:10.1016/s0049-3848(20)30398-4 · Cited by 32
Primer on Biomarker Discovery in Cardio-Oncology
Rhee, J., Ky, B., Armenian, S. H., Yancy, C. W., & Wu, J. C. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.07.006 · Cited by 33
“Another promising genetic biomarker is clonal hematopoiesis of indeterminate potential (CHIP), which has been linked to an increased risk of aging-related conditions including cardiovascular disease (6).”
BackgroundInsights into clonal hematopoiesis and its relation to cancer risk
Mitchell, S. R., Gopakumar, J., & Jaiswal, S. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.004 · Cited by 31
Self-citationBone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Park, E., Evans, M. A., Doviak, H., Horitani, K., Ogawa, H., Yura, Y., Wang, Y., Sano, S., & Walsh, K. X. (2021) · Journal of Visualized Experiments · doi:10.3791/61875 · Cited by 34
Varadarajan, S., Shi, Y., Kaplan, J. H., Ushio‐Fukai, M., & Fukai, T. (2022) · Cells · doi:10.3390/cells11182919 · Cited by 33
Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations
Jakubek, Y. A., Reiner, A. P., & Honigberg, M. C. (2022) · Translational research · doi:10.1016/j.trsl.2022.11.009 · Cited by 33
Prevalence, patterns and outcomes of cardiac involvement in Erdheim–Chester disease
Azoulay, L.-D., Bravetti, M., Aubart, F. C., Emile, J., Seilhean, D., Plu, I., Charlotte, F., Waintraub, X., Carrat, F., Amoura, Z., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac741 · Cited by 31
Akhiyat, N., Lasho, T., Ganji, M., Toya, T., Shi, C., Chen, X., Braggio, E., Ahmad, A., Corban, M., Stewart, K., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318928 · Cited by 31
Ramabadran, R., Wang, J. H., Reyes, J. M., Guzman, A. G., Gupta, S., Rosas, C., Brunetti, L., Gundry, M. C., Tovy, A., Long, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01109-9 · Cited by 35
Moving toward disease modification in polycythemia vera
Bewersdorf, J. P., How, J., Masárová, L., Bose, P., Pemmaraju, N., Mascarenhas, J. O., & Rampal, R. K. (2023) · Blood · doi:10.1182/blood.2023021503 · Cited by 34
Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface
Buttigieg, M. M., & Rauh, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00132 · Cited by 35
“5 in CH carriers, with mutations in JAK2 specifically conferring a 12-fold risk increase for coronary heart disease.(1,2,26) Subsequent cohort analyses and mechanistic studies have verified these initial findings”
BackgroundNoninvasive Techniques for Tracking Biological Aging of the Cardiovascular System
Raisi‐Estabragh, Z., Szabó, L. E., Schuermans, A., Salih, A. M., Chin, C., Vágó, H., Altmann, A., Ng, F. S., Garg, P., Pavanello, S., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.03.001 · Cited by 35
Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome
Bulnes, J. F., González, L., Velásquez, L., Paz, O. M., Venturelli, P. M., & Martínez, G. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1356023 · Cited by 31
“For instance, monocytes/macrophages carrying CHIP-related mutations in Tet2, DNMT3A, or JAK2VF promote in fl ammasome activation, thus exhibiting increased expression of IL-1 and IL-6, alongside other in fl ammatory mediators (79 – 81).”
BackgroundInfluentialDistinct landscape and clinical implications of therapy-related clonal hematopoiesis
Takahashi, K., Nakada, D., & Goodell, M. A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180069 · Cited by 32
“Unexpect-edly, these “control” samples revealed the presence of mutations associated with myeloid malignancies, such as DNMT3A , TET2, ASXL1 , and JAK2 mutations, prompting a reevaluation of these blood samples as reservoirs of somatic mutations rather than pristine controls.”
BackgroundButtigieg, M. M., Vlasschaert, C., Bick, A. G., Vanner, R. J., & Rauh, M. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101989 · Cited by 41
Self-citationIrvin, M. R., Sitlani, C. M., Floyd, J. S., Psaty, B. M., Bis, J. C., Wiggins, K. L., Whitsel, E. A., Stürmer, T., Stewart, J. D., Raffield, L. M., et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz150 · Cited by 31
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Kjær, L. (2020) · Cancers · doi:10.3390/cancers12082100 · Cited by 32
“Although the increased risk for myeloid cancers might be unsurprising in individuals with CH, the data also indicated an unsuspected increased risk of CVD, which was subsequently confirmed [19].”
BackgroundConsidering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction
Tobin, S. W., Alibhai, F. J., Weisel, R. D., & Li, R. (2020) · Cells · doi:10.3390/cells9081894 · Cited by 35
“Clonal hematopoiesis is an age-associated phenomenon which predisposes individuals to hematological cancer and cardiovascular disease [97,98].”
BackgroundInfluentialFate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?
Broxmeyer, H. E., Liu, Y., Kapur, R., Orschell, C. M., Aljoufi, A., Ropa, J. P., Trinh, T. L. P., Burns, S. S., & Capitano, M. L. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10065-y · Cited by 31
Trained Immunity and Cardiometabolic Disease: The Role of Bone Marrow
Mitroulis, I., Hajishengallis, G., & Chavakis, T. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314215 · Cited by 32
Kott, K. A., Vernon, S. T., Hansen, T., de Dreu, M., Das, S. K., Powell, J. E., Groth, B. F. D. S., Bartolo, B. A. D., McGuire, H. M., & Figtree, G. A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017759 · Cited by 31
Tahri, S., Mouhieddine, T. H., Redd, R. A., Lampe, L. M., Nillson, K., El‐Khoury, H., Su, N. K., Nassar, A. H., Adib, E., Bindra, G. S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004926 · Cited by 31
“036).(1,13) Whether survival differences will become apparent with longer follow-up remains unknown.”
Denicolò, S., Vogi, V., Keller, F., Thöni, S., Eder, S., Heerspink, H. J. L., Rosivall, L., Więcek, A., Mark, P. B., Perco, P., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.01.1064 · Cited by 30
“15,22 Thus, it seemed reasonable to hypothesize that CHIP would also increase the risk of kidney function decline in T2DM, a condition where micro-in fl ammation plays a major role.”
BackgroundInfluentialPasterkamp, G., den Ruijter, H. M., & Giannarelli, C. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316693 · Cited by 31
Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients
Scolari, F. L., Brahmbhatt, D. H., Abelson, S., Medeiros, J. J. F., Anker, M. S., Fung, N. L., Otsuki, M., Arguelles, O. C., Lawler, P. R., Ross, H. J., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17172 · Cited by 30
Role of ASXL1 in hematopoiesis and myeloid diseases
Gao, X., You, X., Droin, N. M., Banaszak, L. G., Churpek, J. E., Padron, E., Geissler, K. H., Solary, É., Patnaik, M. M., & Zhang, J. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.003 · Cited by 31
Clonal Hematopoiesis in Young Women Treated for Breast Cancer
Gibson, C. J., Fell, G. G., Sella, T., Sperling, A. S., Snow, C., Rosenberg, S. M., Kirkner, G. J., Patel, A., Dillon, D. A. R., Bick, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0050 · Cited by 33
Self-citationTelomere biology: from disorders to hematological diseases
Roka, K., Solomou, E. E., & Kattamis, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167848 · Cited by 33
“That said, recent data show that young patients with CHIP are at an increased risk of developing not only hematological malignancies but also coronary heart disease, cardiovascular events, and stroke (72, 73).”
BackgroundNeutrophil-mediated innate immune resistance to bacterial pneumonia is dependent on Tet2 function
Quin, C., DeJong, E. N., Cook, E. K., Luo, M., Vlasschaert, C., Sadh, S., McNaughton, A. J. M., Buttigieg, M. M., Breznik, J. A., Kennedy, A. E., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171002 · Cited by 30
Self-citationGulej, R., Patai, R., Ungvari, A., Kállai, A., Tarantini, S., Yabluchanskiy, A., Huffman, D. M., Conboy, M. J., Conboy, I. M., Kivimäki, M., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01657-y · Cited by 32
The global epidemiology of acute myeloid leukaemia
Chaer, F. E., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01099-7 · Cited by 39
“Clonal haematopoiesis becomes increasingly prevalent with age, manifesting in 20–30% of individuals >60 years of age 97,98 .”
Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging
Kosan, C., Heidel, F. H., Godmann, M., & Bierhoff, H. (2018) · Cells · doi:10.3390/cells7120237 · Cited by 29
Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis
Verma, D., Kumar, R., Pereira, R. S., Karantanou, C., Zanetti, C., Minciacchi, V. R., Fulzele, K. S., Kunz, K., Hoelper, S., Chahabi, S. Z., et al. (2019) · Blood · doi:10.1182/blood.2018874214 · Cited by 32
Mangaonkar, A. A., Ferrer, A., Vairo, F. P. E., Cousin, M. A., Kuisle, R. J., Gangat, N., Hogan, W. J., Litzow, M. R., McAllister, T. M., Klee, E. W., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.007 · Cited by 29
Biological implications of clonal hematopoiesis
Luis, T. C., Wilkinson, A. C., Beerman, I., Jaiswal, S., & Shlush, L. I. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.08.004 · Cited by 30
Self-citationHoughton, D. E., Koh, I., Ellis, A. M., Key, N. S., Douce, D., Howard, G., Cushman, M., Safford, M. M., & Zakai, N. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25703 · Cited by 33
Implications of Clonal Hematopoiesis for Precision Oncology
Miller, P. G., & Steensma, D. P. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00144 · Cited by 33
Aging and leukemic evolution of hematopoietic stem cells under various stress conditions
Kurosawa, S., & Iwama, A. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00138-3 · Cited by 31
“9 times more frequently in individuals with ARCH/CHIP than in those without ARCH/CHIP [107].”
BackgroundPrecision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 30
Metadata
- Authors
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- ORCID
- Jaiswal, Siddhartha
- Natarajan, Pradeep
- Silver, Alexander J.
- Gibson, Christopher J.
- Bick, Alexander G.
- McConkey, Marie
- Gupta, Namrata
- Gabriel, Stacey
- Ardissino, Diego
- Baber, Usman
- Mehran, Roxana
- Danesh, John
- Saleheen, Danish
- Melander, Olle
- Sukhova, Galina K.
- Neuberg, Donna
- Libby, Peter
- Kathiresan, Sekar
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-13
- Volume
- 377
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6717509
- OpenAlex
- W2628145035
- Cited by
- 2,683
- References
- 37
- Citations by year
- 2026: 303 · 2025: 322 · 2024: 347 · 2023: 338 · 2022: 371 · 2021: 303 · 2020: 263 · 2019: 215 · 2018: 169 · 2017: 44
- FWCI
- 143.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL082945, R01HL080472, RC2HL101834, T32HL116324)
- National Human Genome Research Institute (U54HG003067)
- Fogarty International Center (RC1TW008485)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- clonal hematopoiesis of indeterminate potential, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, coronary artery calcification, TET2 mutation, DNMT3A, ASXL1, JAK2, somatic mutations, atherosclerosis, cytokines and chemokines, macrophages, bone marrow transplantation
- MeSH terms
- Animals, Coronary Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Risk, Case-Control Studies, Sequence Analysis, DNA, Mice, Knockout, Genetic Predisposition to Disease, Atherosclerosis, Mice, Exome, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.